InflaRx IFRX 深 沪
等待开盘 09-09 09:30:00 美东时间
1.58
-0.070
-4.24%
华盛通- 最 高1.605
- 今 开1.57
- 成交量 68.13万股
- 最 低 1.53
- 昨 收 1.65
- 总市值 1.07亿
- 52周最高 2.815
- 市盈率 静 --
- 换手率 1.01%
- 52周最低 0.7113
- 委 比 3.69%
- 总股本 6774.71万
- 历史最高 53.10
- 量 比 0.35
- 振 幅 4.55%
- 历史最低 0.7113
- 每 手 1
- 风险率 0.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge
Several biotech stocks are showing renewed strength over the past week, with their Momentum scores soaring in Benzinga's Edge Stock Rankings.
09-08 17:59
HC Wainwright & Co. Assumes InflaRx at Buy, Announces Price Target of $6
HC Wainwright & Co. analyst Matthew Keller assumes InflaRx (NASDAQ:IFRX) with a Buy rating and announces Price Target of $6.
09-02 18:49
InflaRx Announces Participation in September Investor Conferences
InflaRx N.V. will participate in two investor conferences in September 2025: the Cantor Global Healthcare Conference in New York on September 4th and the H.C. Wainwright Global Investment Conference on September 9th. They will present and hold one-on-one meetings. Links to the live streams and replays are available. rtc sean的SDKキー
08-21 11:30
InflaRx shares are trading lower after the company reported worse-than-expected Q2 financial results.
InflaRx shares are trading lower after the company reported worse-than-expected...
08-07 22:46
InflaRx Q2 EPS $(0.24) Misses $(0.17) Estimate, Sales $44.708K Miss $50.167K Estimate
InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.17) by 38.73 percent. This is a 7.69 percent increase over losses of $(0.26) per share from the same
08-07 19:36
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
美国“集采”扰动外盘，中国创新药或受益，创新药ETF沪港深（159622）场内价格年内涨超51%
8月5日早盘，创新药ETF沪港深（159622）场内价格迅速涨近1.4%，成份股沃森生物、泽璟制药、百利天恒领涨，百济神州、信达生物、康方生物涨超2%，药明康德...
08-05 11:39
InflaRx to Report Second Quarter 2025 Results on August 7, 2025
InflaRx N.V. will release its Q2 2025 financial and operational results on August 7, 2025. The company, specializing in anti-inflammatory therapies targeting the complement system, focuses on developing inhibitors of C5a and its receptor. InflaRx's vilobelimab, an anti-C5a monoclonal antibody, has shown effective clinical activity, and the company is also developing INF904, an oral C5a receptor signaling inhibitor. Founded in 2007, InflaRx operat...
07-31 11:30
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
InflaRx N.V. received a notice from Nasdaq regarding its common shares trading below the $1.00 minimum bid price requirement for 30 consecutive days. The company has 180 days until January 7, 2026, to regain compliance. If unsuccessful, it may transfer its listing to the Nasdaq Capital Market, potentially gaining an additional 180 days to meet the requirement. The notice does not affect current trading, and InflaRx plans to monitor share prices a...
07-11 20:15
Jasper Therapeutics Shares Fall On Briquilimab Drug Lot Problem
Jasper shares drop after updated BEACON study shows strong results but faces disruption from compromised drug product lot and halted pipeline programs.
07-08 01:25
